Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A Phase 1b/2a study to evaluate the safety, tolerability and pharmacokinetics of multiple
ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful
diabetic neuropathy.